A recent review43 also highlighted the risk of QT-interval prolongation and cardiomyopathy attributable to the possibility of interaction between apixaban and hydroxychloroquine because of a mechanism of inhibition of CYP2C8 and P-glycoprotein. Here, CYP2C8 is linked to cardiomyopathy.